A Placebo-Controlled, Phase 1, Single and Multiple IV [intravenous] Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of C326 in Adults With Crohn's Disease

Trial Profile

A Placebo-Controlled, Phase 1, Single and Multiple IV [intravenous] Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of C326 in Adults With Crohn's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs AMG 220 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Sponsors Avidia
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top